Investigational Agents for the Treatment of Resistant Yeasts and Molds.

IF 2.3 Q3 INFECTIOUS DISEASES

Current Fungal Infection Reports Pub Date : 2021-01-01 Epub Date: 2021-05-28 DOI:10.1007/s12281-021-00419-5

Garret T Seiler, Luis Ostrosky-Zeichner

{"title":"Investigational Agents for the Treatment of Resistant Yeasts and Molds.","authors":"Garret T Seiler, Luis Ostrosky-Zeichner","doi":"10.1007/s12281-021-00419-5","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review summarizes the investigational antifungals in clinical development with the potential to address rising drug resistance patterns. The relevant pharmacodynamics, spectrum of activity, preclinical studies, and latest clinical trial data are described.Recent findings: Agricultural and medicinal antifungal use has been selected for inherently drug-resistant fungi and acquired resistance mechanisms. The rates of fungal infections and immunocompromised populations continue to grow as few new antifungals have hit the market. Several agents with the potential to address the emergence of multidrug-resistant (MDR) molds and yeasts are in clinical development.Summary: Evolved formulations of echinocandins, polyenes, and triazoles offer less toxicity, convenient dosing, and greater potency, potentially expanding these classes' indications. Ibrexafungerp, olorofim, oteseconazole, and fosmanogepix possess novel mechanisms of actions with potent activity against MDR fungi. Successful clinical development is neither easy nor guaranteed; thus, perpetual efforts to discover new antifungals are needed.","PeriodicalId":10813,"journal":{"name":"Current Fungal Infection Reports","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12281-021-00419-5","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Fungal Infection Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12281-021-00419-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/5/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 17

Abstract

Purpose of review: This review summarizes the investigational antifungals in clinical development with the potential to address rising drug resistance patterns. The relevant pharmacodynamics, spectrum of activity, preclinical studies, and latest clinical trial data are described.

Recent findings: Agricultural and medicinal antifungal use has been selected for inherently drug-resistant fungi and acquired resistance mechanisms. The rates of fungal infections and immunocompromised populations continue to grow as few new antifungals have hit the market. Several agents with the potential to address the emergence of multidrug-resistant (MDR) molds and yeasts are in clinical development.

Summary: Evolved formulations of echinocandins, polyenes, and triazoles offer less toxicity, convenient dosing, and greater potency, potentially expanding these classes' indications. Ibrexafungerp, olorofim, oteseconazole, and fosmanogepix possess novel mechanisms of actions with potent activity against MDR fungi. Successful clinical development is neither easy nor guaranteed; thus, perpetual efforts to discover new antifungals are needed.

Abstract Image

查看原文本刊更多论文

治疗耐药酵母菌和霉菌的药物研究。

综述目的:本文综述了临床开发中的抗真菌药物，这些抗真菌药物具有解决日益增长的耐药模式的潜力。描述了相关的药效学、活性谱、临床前研究和最新的临床试验数据。最近的发现:农业和药用抗真菌使用已选择固有耐药真菌和获得性耐药机制。真菌感染和免疫功能低下人群的比率继续增长，因为很少有新的抗真菌药物进入市场。几种有可能解决耐多药霉菌和酵母菌出现的药物正在临床开发中。总结:棘白菌素、多烯和三唑的进化配方毒性更小，给药方便，效力更强，潜在地扩大了这些类别的适应症。Ibrexafungerp, olorofim, oteseconazole和fosmanogepix具有新的作用机制，对MDR真菌具有有效的活性。成功的临床开发既不容易也不保证;因此，需要不断努力发现新的抗真菌药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Fungal Infection Reports INFECTIOUS DISEASES-

CiteScore

3.10

自引率

7.10%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of fungal infections. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as advances in diagnosis, current and emerging management approaches, and genomics and pathogenesis. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. Commentaries from well-known figures in the field are also provided, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.

文献相关原料

公司名称	产品信息	采购帮参考价格